ChatGPTを活用して業務のAI化を進めています。プロンプトエンジニアリングの専門家です！と、名乗れるレベルではありませんが、かなり色々使いこなしてきています。この１年、病気で失われた能力は、別な能力を発達させる、進化することで生き残っていこうと思います。
<><><>
23/07/07
Low-level ambient sulfur dioxide exposure and genetic susceptibility associated with incidence of idiopathic pulmonary fibrosis: A national prospective cohort study
X Wang, X Deng, Y Wu, Z Qian, M Cai, H Li, H Lin - Chemosphere, 2023
… idiopathic pulmonary fibrosis (IPF) has been established, but the evidence regarding the effect of low levels of air pollution, especially ambient sulfur dioxide (SO 2 ), is limited. Besides, the combined effect and interaction between genetic …
- 低レベルの周囲二酸化硫黄曝露と特発性肺線維症の発生に関連する遺伝的感受性：全国的な前向きコホート研究
Expression and protective effect of chemerin in idiopathic pulmonary fibrosis
CY Shen, GR Li, D Wei, W Wang, XS Yang, C Jiang… - Zhonghua jie he he hu xi za …, 2023
… Objective: To explore the expression and the role of chemerin in idiopathic pulmonaryfibrosis (IPF). Methods: Quantitative PCR and … IPF. Chemerin may play a protective role in the development of IPF by regulating EMT, providing a new idea …
- 特発性肺線維症におけるケマリンの発現と保護効果
Single-Cell RNA-seq Provides New Insights into Therapeutic Roles of Thyroid Hormone in the Idiopathic Pulmonary Fibrosis
L Wang, Z Li, R Wan, X Pan, B Li, H Zhao, J Yang… - American Journal of …, 2023
… Idiopathic Pulmonary fibrosis (IPF) is a progressive fatal interstitial lung disease without effective cure. Herein, we explore the role of 3,5,3’-… T3 enhanced the resolution of pulmonary fibrosis by promoting the differentiation of Krt8+ transitional …
NETosis promotes chronic inflammation and fibrosis in systemic lupus erythematosus and COVID-19
H Lin, J Liu, N Li, B Zhang, P Yao, J Feng, Q Liu… - Clinical Immunology, 2023
… In this study, we revealed the landscape of transcriptional changes in lung biopsies from individuals with SLE, COVID-19-induced pulmonary fibrosis, and idiopathic pulmonaryfibrosis (IPF) using histopathology and RNA sequencing …
[PDF] Critical Care Management of Lung Fibrosis, Review Article
AR Alharbi, BM Alotaibi - Journal of Medicine and Healthcare. SRC/JMHC-284 …, 2023
… Idiopathic pulmonary fibrosis is considered to be one of the most common types of … The worldwide statistics highlight that every 13 to 20 individuals in a population of 1,00,000 witnesses the prevalence of pulmonary fibrosis [3]. Idiopathic pulmonary …
- 肺線維症の救命救急管理、総説論文
23/07/05
Management of patients with idiopathic pulmonary fibrosis and lung cancer: challenges in clinical practice
T Karampitsakos, F Sampsonas, JD Herazo-Maya… - Current opinion in pulmonary …
… Purpose of review: Idiopathic pulmonaryfibrosis (IPF) is the nonmalignant, chronic lung disease with the worst prognosis. Prevalent … of patients with IPF and lung cancer and highlights future perspectives. Recent findings: Recent registries for …
- 特発性肺線維症および肺がん患者の管理: 臨床現場での課題
Downregulation of a potential therapeutic target NPAS2, regulated by p53, alleviates pulmonary fibrosis by inhibiting epithelial-mesenchymal transition via …
Y Chen, Z He, B Zhao, R Zheng - Cellular Signalling, 2023
… Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease and a severe form of pulmonary fibrosis. Epithelial-mesenchymal … lung parenchyma and contributes to pulmonaryfibrosis. NPAS2 (neuronal PAS domain protein 2) is …
- p53によって制御される潜在的な治療標的NPAS2の下方制御は、HES1の抑制を介して上皮間葉転換を阻害することにより肺線維症を軽減する
[PDF] Potential Therapeutic Uses of Thalidomide for Pulmonary Fibrosis
N Rashidpour, S Karami-mohajeri, A Farsinejad… - Journal of Pharmaceutical …, 2023
… Also, Thalidomide gained attention as a suitable agent for the treatment of cough associated with idiopathic pulmonary fibrosis(IPF) and for severe pulmonary damage cause by severe acute respiratory syndrome, coronavirus 2 (SARS-CoV-2) …
Vimentin-targeted radiopeptide 99mTc-HYNIC-(tricine/EDDA)-VNTANST: a promising drug for pulmonary fibrosis imaging
M Rezaeianpour, SM Mazidi, R Nami, P Geramifar… - Nuclear Medicine …, 2023
… Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by the accumulation of extracellular matrix. Because there is no effective treatment for advanced IPF to … Idiopathicpulmonary fibrosis (IPF) is a chronic and fatal lung …
- ビメンチン標的放射性ペプチド 99mTc-HYNIC-(トリシン/EDDA)-VNTANST: 肺線維症イメージングに有望な薬剤
[HTML] Diagnostic Accuracy of Immature Platelet Fraction (IPF) to Differentiate Between Thrombocytopenia due to Peripheral Destruction versus Bone Marrow Failure
MB Asghar, F Akhtar, A Mahmood, N Rafique, NA Rana… - Age (years)
… ; 43 were obtained from patients having hyperdestructive thrombocytopenia (idiopathicthrombocytopenia, thrombotic thrombocytopenic purpura, … Sysmex automated haematology analyzer, XN-3000 was used to determine the immature platelet …
- 末梢破壊による血小板減少症と骨髄不全による血小板減少症を区別するための未熟血小板画分（IPF）の診断精度
Inhalable dry powder containing lipid polymer hybrid nanoparticles of Nintedanib esylate: In vitro and in vivo evaluations
M Patel, S Karampuri, V Kansara, B Vyas - Journal of Drug Delivery Science and …, 2023
… The key objective of this research work was to develop and evaluate dry powder for inhalation containing lipid polymer hybrid nanoparticles (LPHNPs) loaded with Nintedanib esylate (NE) to target deep lung for the treatment of idiopathicpulmonary …
- エシル酸ニンテダニブの脂質ポリマーハイブリッドナノ粒子を含む吸入可能な乾燥粉末: in vitro および in vivo 評価
Human senescent fibroblasts trigger progressive lung fibrosis in mice.
F Hernandez-Gonzalez, N Prats, V Ramponi… - Aging, 2023
… Cell senescence has recently emerged as a potentially relevant pathogenic mechanism in fibrosing interstitial lung diseases (f-ILDs), particularly in idiopathic pulmonary fibrosis. We hypothesized that senescent human fibroblasts may suffice …
- ヒトの老化線維芽細胞は、マウスの進行性肺線維症を引き起こします。
23/07/04
[HTML] Re-hospitalisation predicts poor prognosis after acute exacerbation of interstitial lung disease
J Salonen, S Jansa, H Vähänikkilä, R Kaarteenaho - BMC Pulmonary Medicine, 2023
… Fifty-three patients with idiopathicpulmonary fibrosis (IPF) and 42 patients with other ILD were … In a univariate model, IPFdiagnosis, high age and a non-elective respiratory re-hospitalisation … with poor survival time in both idiopathic pulmonary …
- 間質性肺疾患の急性増悪後の再入院は予後不良を予測する
[PDF] Re-hospitalisation predicts poor prognosis after acute exacerbation of interstitial lung
J Salonen, S Jansa, H Vähänikkilä, R Kaarteenaho - 2023
… Results Fifty-three patients with idiopathicpulmonary fibrosis (IPF) and 42 patients with other ILD were … In a univariate model, IPFdiagnosis, high age and a non-elective respiratory re-… idiopathic pulmonary fibrosis(IPF) and in other types …
- 間質性肺の急性増悪後の再入院は予後不良を予測する
Real world experience with nintedanib in connective tissue disease-related interstitial lung disease: a retrospective cohort study
M Barešić, S Novak, D Perković, B Karanović, F Mirić… - Clinical Rheumatology, 2023
… Positive results from the registration studies of nintedanib led to approval of the drug for the treatment of idiopathic pulmonary fibrosis and chronic fibrosing interstitial lung diseases in connective tissue diseases. After registration, real-world …
23/07/03
[PDF] Active transcription in the vascular bed characterizes rapid progression in idiopathic pulmonary fibrosis
NS Sharma, K Patel, E Sari, S Shankar… - The Journal of Clinical …, 2023
… Idiopathic Pulmonary Fibrosis (IPF) is the most common manifestation of interstitial lung disease (ILD), with a median survival of 3-5 years after diagnosis. IPF … Despite the short median survival, there is a striking variance in the clinical course of …
- 血管床における活発な転写は、特発性肺線維症の急速な進行の特徴となる
[PDF] Idiopathic pulmonary fibrosis therapy development: a clinical pharmacology perspective
TH Mai, LW Han, JC Hsu, N Kamath, L Pan - Therapeutic Advances in Respiratory …, 2023
… Idiopathic pulmonary fibrosis (IPF) is a subtype of interstitial lung disease (ILD) that has no known cause or cure. A poor understanding of … phenotype of ILD, with idiopathic interstitial pneumonia (IIP) diagnosed if no cause is identified. Notably …
- 特発性肺線維症治療法の開発: 臨床薬理学の観点
[HTML] Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies
J Behr, SD Nathan, U Costabel, C Albera, WA Wuyts… - Advances in Therapy, 2023
… In the European Union (EU), the indication for the antifibrotic pirfenidone prior to April 2023 did not include patients with advanced idiopathicpulmonary fibrosis (IPF). This analysis compared the efficacy and safety of pirfenidone in advanced IPF …
- 進行性特発性肺線維症と非進行性特発性肺線維症におけるピルフェニドンの有効性と安全性：6つの臨床研究の事後分析
[PDF] Presence of anti‐modified protein antibodies in idiopathic pulmonary fibrosis
D Kalafatis, V Joshua, M Hansson, L Mathsson‐Alm… - Respirology, 2023
… We show that multiple anti-modified protein antibodies are present in a significant proportion of patients with idiopathic pulmonary fibrosis(IPF). Antibodies against anti-modified peptides were present in patients despite having no antibodies against anti-cyclic …
- 特発性肺線維症における抗修飾タンパク質抗体の存在
[HTML] Radiological findings based comparison of functional status in patients who have post-covid lung injury or idiopathic pulmonary fibrosis
D Kızılırmak, S Sarı, F Can, Y Havlucu - BMC Pulmonary Medicine, 2023
… At radiologic evaluation, ground glass opacity scores were higher in patients with post-COVID lung injury, whereas pulmonary fibrosis scores were higher in patients with idiopathicpulmonary fibrosis. However, the total severity scores were similar …
External Control Arms in Idiopathic Pulmonary Fibrosis Using Clinical Trial and Real World Data Sources
AC Swaminathan, LD Snyder, H Hong, SR Stevens… - American Journal of …, 2023
Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease for which novel therapies are needed. External controls (ECs) could enhance IPF trial efficiency, though the direct comparability of ECs to concurrent controls is unknown …
- 臨床試験と現実世界のデータソースを使用した特発性肺線維症における外部制御アーム
Usefulness of a new parameter in functional assessment in patients with idiopathic pulmonary fibrosis: desaturation-distance ratio from the six-minute walk test
R Aktan, KC Tertemiz, S Yiğit, S Özalevli, AÖ Alpaydın… - Sarcoidosis, vasculitis, and …, 2023
… ) are needed for assessing exercise capacity in patients with idiopathic pulmonary fibrosis(IPF). To our knowledge, no previous study has … in patients with IPF. This study aimed to investigate whether DDR is a potential tool for assessing …
- 特発性肺線維症患者の機能評価における新しいパラメーターの有用性: 6 分間歩行テストからの非飽和距離比
[HTML] Lung transplant recipients with telomere-mediated pulmonary fibrosis have increased risk for hematologic complications
SJ Hannan, CJ Iasella, RM Sutton, ID Popescu… - American Journal of …, 2023
… Idiopathic pulmonary fibrosis lung transplant recipients (IPF-LTRs) are enriched for short … We hypothesized that IPF-LTRs with short-TL and/or rare variants would be at increased risk … Idiopathic pulmonary fibrosis(IPF) is the leading indication …
- テロメア媒介性肺線維症を患う肺移植レシピエントでは、血液合併症のリスクが増加する
Adipokines in interstitial lung diseases
M Zielinski, A Chwalba, D Jastrzebski, D Ziora - Respiratory Physiology & …, 2023
… In acute exacerbation of idiopathicpulmonary fibrosis, higher levels of adiponectin and leptin are observed compared to stable disease, thus, it correlated with worse survival. Their role in the regulation of peroxisome proliferator-activated …
- 間質性肺疾患におけるアディポカイン
[PDF] Suppression of NLRP3 inflammasome by ivermectin ameliorates bleomycin-induced pulmonary fibrosis
MA Abd-Elmawla, HR Ghaiad, ES Gad, KA Ahmed… - Journal of Zhejiang …, 2023
… activation to protect from bleomycin-induced pulmonary fibrosis. Sci Rep, 9: 19643. … Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 … Efficacy of simtuzumab versus placebo in patients with idiopathic …
- イベルメクチンによるNLRP3インフラマソームの抑制はブレオマイシン誘発性肺線維症を改善する
<><><>
特発性肺線維症( idiopathic pulmonary fibrosis (IPF) )関連の学術的情報収集してシェアしています。Google Scholar SearchのUpdateを定期的に掲載しています。GoogleのAIが一定の重み付けはしているとは思いますが、玉石混交です。
当面、毎週アラートの内容をアップしていこうと思います。
###
